Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope

BACKGROUND: There are few therapeutic options available for patients with B-cell acute lymphoblastic leukemia (B-ALL) relapsing as CD19(–) either after chemotherapy or CD19-targeted immunotherapies. CD22-chimeric antigen receptor (CAR) T cells represent an attractive addition to CD19-CAR T cell ther...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Immunother Cancer
Hoofdauteurs: Velasco-Hernandez, Talia, Zanetti, Samanta Romina, Roca-Ho, Heleia, Gutierrez-Aguera, Francisco, Petazzi, Paolo, Sánchez-Martínez, Diego, Molina, Oscar, Baroni, Matteo Libero, Fuster, Jose Luis, Ballerini, Paola, Bueno, Clara, Fernandez-Fuentes, Narcis, Engel, Pablo, Menendez, Pablo
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BMJ Publishing Group 2020
Onderwerpen:
Immune Cell Therapies and Immune Cell Engineering
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7422657/
https://ncbi.nlm.nih.gov/pubmed/32788237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000896
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items